Article Text

other Versions

PDF
Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base.
  1. U A Walker (ulrich.walker{at}fps-basel.ch)
  1. Basle University Dept. of Rheumatology, Switzerland
    1. A Tyndall (alan.tyndall{at}fps-basel.ch)
    1. Basle University Dept. of Rheumatology, Switzerland
      1. L Czirják (laszlo.czirjak{at}aok.pte.hu)
      1. University of Pécs, Hungary
        1. C P Denton
        1. Royal Free and University College London Medical School, United Kingdom
          1. D Farge Bancel (dominique.farge-bancel{at}sls.ap-hop-paris.fr)
          1. Hopital Saint Louis, Paris, France
            1. O Kowal-Bielecka
            1. Medical University of Bialystok, Poland
              1. U Müller-Ladner (u.mueller-ladner{at}kerckhoff-klinik.de)
              1. Kerckhoff-Klinik Bad Nauheim, Germany
                1. C Bocelli-Tyndall (chiara.tyndall{at}fps-basel.ch)
                1. Basle University Dept. of Rheumatology, Switzerland
                  1. M Matucci-Cerinic (cerinic{at}unifi.it)
                  1. University of Florence, Italy
                    1. EUSTAR Co-authors
                    1. EUSTAR, Switzerland

                      Abstract

                      Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the skin involvement. In order to better understand the vascular, immunological and fibrotic processes of SSc and to guide its treatment the EULAR Scleroderma Trials And Research (EUSTAR) group was formed in June 2004.

                      Aims and Methods: EUSTAR collects prospectively the Minimal Essential Data Set (MEDS) on all sequential patients fulfilling the ACR diagnostic criteria in participating centres. We aimed to characterize demographic, clinical and laboratory characteristics of disease presentation in SSc and analysed EUSTAR baseline visits.

                      Results: In April 2006, a total of 3656 patients (1349 with dcSSc and 2101 with lcSSc) were enrolled in 102 centres and 30 countries. 1330 individuals had autoantibodies against Scl70 and 1106 against anticentromere antibodies. 87% of patients were female. On multivariate analysis, scleroderma subsets (dcSSc vs. lcSSc), antibody status and age at onset of Raynaud’s phenomenon, but not gender were independently associated with the prevalence of organ manifestations. Autoantibody status in this analysis appeared more closely associated with clinical manifestations than were SSc subsets.

                      Conclusion: dcSSc and lcSSc subsets are associated with particular organ manifestations, but in this analysis the clinical distinction appeared superseded by an antibody based classification in predicting some scleroderma complications. The EUSTAR MEDS data base facilitates the analysis of clinical patterns in SSc and contributes to the standardised assessment and monitoring of SSc internationally.

                      • EULAR
                      • autoantibodies
                      • cohort studies
                      • scleroderma
                      • systemic sclerosis

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.